WealSee Completes Multi-Million RMB Angel+ Round to Advance Intelligent Digital Solutions for Juvenile Myopia Control

VCBeat learned at the first time,Wellsees (hereinafter referred to as“Wellsees”）Announced the completion byShanghaiFengcang Innovation FundAndFamous Investor and Gold Medal Secretary of the Board, Mr. An JiangboCo-investedMillions of RMB in Angel RoundFinancing. The funds raised will be used for the clinical registration of the company's core projects.

Wellsees was founded in November 2019.，Focusing on the core track of adolescent myopia precision prevention and control and eye health management.The company team is composed of professional elites, including the professor team from the Department of Optometry at the Hong Kong Polytechnic University, the professor team from Shenzhen University, as well as technical talents and senior management from Huawei and Mindray. It is one of the few in China.A company that masters the full-process digitalization and intelligent technology for contact lens design, manufacturing, and fitting.

In 2021, Wellsees built a 1,500-square-meter GMP production base in Longgang, Shenzhen, and completed the acceptance.Has the largest GMP rigid endoscope production base in South China.

Wellsees, focusing on unmet needs in clinical and real-world optometry scenarios, has dedicated itself to research and development, innovatively launchingFull-lens toric design OK lens, portable corneal topographer, and intelligent fitting and AI software systemCan respectively achieve better myopia prevention and control effects, expand service scenarios in traditional corneal detection, improve service quality, effectively avoid manual calculation and processing errors as well as omissions of non-standard characteristics, and ensure the quality of processing technology.(For more details, see: "With a Top Cross-Disciplinary Expert Team and the Largest GMP Rigid Lens Production Base in South China, How Does Wellsees Tackle the One-Stop Service for Rigid Contact Lenses?")

With the vision and original intention of "using scientific and technological innovation to make teenagers' eye use healthier and brighter," Wellsees, after years of dedicated efforts, has achieved several phased results this year——

First, it obtained the ISO13485 certification for international medical device quality management systems issued by the internationally authoritative institution SGS, and acquired the qualifications for operating Class II and Class III medical devices. Subsequently, it successfully held the OK lens clinical trial kickoff meeting with Guangzhou Haibot, a professional CRO company, as well as the leading unit and all participating research units, vigorously advancing various clinical registration tasks. As a member unit of the Shenzhen Eye Optometry Association and the Shenzhen Medical Device Quality Management Promotion Association, Wellsees recently stood out among competitors to be listed in the "Top 100 Emerging Chinese High-Performance Medical Device Companies in 2022."

For this round of financing,Wellsees Founder Zhang Jing"Wellsees' rapid development is inseparable from the strong support of the company's shareholders, as well as the professionalism and hard work of the team. The company will remain committed to the eye health sector, leveraging technological innovation, product innovation, and professional insights into the eye health industry to provide unprecedented and enhanced product experiences for those in need of eye health services through technological means."”

Wellsees focuses on five major ophthalmic fields: myopia control and eye growth development, ophthalmic drug research and delivery, vision enhancement for middle-aged and elderly people, ocular surface and tear film, and advanced optometry technologies. The company consistently invests in R&D that integrates medical research, education, and industry-commercialization of products. In alignment with China's national eye health planning, Wellsees builds its medical expertise to serve the eye health needs of the Chinese population.

While rapidly advancing the domestic registration of products such as OK lenses, RGP, scleral lenses, and corneal topographers in China, we are also vigorously expanding into overseas markets. Our team, which includes cross-disciplinary technical experts, possesses a high degree of international perspective. We have established overseas sales companies in Singapore and Hong Kong to handle product registration and sales abroad. Currently, we have reached cooperation agreements with several distributors in Southeast Asia, enabling large-scale sales of our products in the region, achieving success outside that enhances our reputation within.

Famous Investor and Gold Medal Secretary of the Board, An Jiangbo"Myopia prevention and control, eye health management, etc., have been upgraded as one of the important national strategies. The Wellsees team has made the right track choice, and I firmly believe in Wellsees. With very rich underlying R&D capabilities, I believe that under the leadership of such a young and creative team, Wellsees will make significant contributions to teenagers' eye health and society in the future. As an investor, I support teams with aspirations and industries with a future, mobilizing various resources to provide help and support, and look forward to a bright and promising future together with Wellsees!"”

Hong Yuanchuan, Investment Manager of Jiaxing Fengquan Medical Industry Equity Investment Partnership (L.P.)"It is reported that the number of myopia patients in China is about 600 million, including approximately 100 million teenagers. Orthokeratology lenses are currently one of the best measures for myopia prevention and control. The current penetration rate is low, indicating significant room for industry growth, and the impact of the pandemic on the industry has been relatively small. The Wellsees team comes from prestigious universities and enterprises such as the Hong Kong Polytechnic University, Shenzhen University, and Mindray. It is one of the few companies in China that fully masters the entire process technology of intelligent AI design, precise fitting, and high-precision processing of rigid contact lenses. The team is highly professional and capable of providing integrated solutions with innovative technologies. We look forward to the company completing domestic registration and achieving its IPO soon."

Fundaxe Capital, a Multi-Family Office and licensed equity investment institution, provides investment, tax, education, and other services to high-net-worth and listed company families.

In the industry, Fengcang Innovation Fund focuses on investing in the next generation of "automotive and biopharmaceuticals" sectors. It has established an ecosystem for the next generation of automobiles, including companies like Zhuhai CosMX Battery (688772), Fangyuan Environmental Protection (688148), Jinmei New Materials, Jinko Electronics, and Shixin New Materials. Additionally, it supports biopharmaceutical service enterprises with synergistic effects, such as Aesica CDMO, Kaiji Bio (835272), Smart, and MicroLight Gene. Committed to the mission of "Investing to Change the World," it serves great enterprises in China.